SCHEMBL15840773

SCHEMBL15840773

Cc1ccc2c(C)nc(Nc3nc(C)c(CCC(C)C)c(=O)[nH]3)nc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.69
ALDH1A1 P00352 10/20 0.69
HSD17B10 Q99714 1/20 0.69
SMN1; SMN2 Q16637 5/20 0.64
RAB9A P51151 3/20 0.58
HTT P42858 4/20 0.58
NPSR1 Q6W5P4 3/20 0.58
ALOX15 P16050 1/20 0.58
LMNA P02545 5/20 0.56
XBP1 P17861 3/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CREBBP Q92793 2/20 0.54
USP2 O75604 3/20 0.52
TSHR P16473 2/20 0.52
KMT2A Q03164 5/20 0.52
NPC1 O15118 1/20 0.52
CLK1 P49759 1/20 0.52
MEN1 O00255 2/20 0.51
STAT3 P40763 3/20 0.47
CYP1A2 P05177 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840713 0.92 MAPT (0.79) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL15840828 0.89 MAPT (0.66) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL15840614 0.87 MAPT (0.64) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL15840677 0.86 MAPT (0.69) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL2465457 0.86 ALDH1A1 (0.77) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL15840752 0.83 CREBBP (0.74) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL23657581 0.83 ALDH1A1 (0.60) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL5991672 0.83 MAPT (0.66) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL15840748 0.83 MAPT (0.75) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A
SCHEMBL15840758 0.82 MAPT (1.00) MAPTALDH1A1HSD17B10SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885ALDH1A1 4348/4885HSD17B10 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.